Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Phase 3 clinical trial of ambroxol for Parkinson’s confirmed
Phase 3 clinical trial of ambroxol for Parkinson’s confirmed
Cure Parkinson’s is delighted to announce that following promising results reported at phase 2 in 2020, a large-scale phase 3 clinical trial of ambroxol, a drug currently in use to treat respiratory...
US FDA approves AstraZeneca-Avillion’s asthma treatment Airsupra
US FDA approves AstraZeneca-Avillion’s asthma treatment Airsupra

The US Food and Drug Administration (FDA) has approved AstraZeneca and Avillion’s Airsupra (albuterol/budesonide), to treat asthma.

FDA rejects Biocon insulin biosimilar over data, manufacturing concerns
FDA rejects Biocon insulin biosimilar over data, manufacturing concerns
Biocon already produces a biosimilar copycat of Sanofi's Lantus. But its submission for its knockoff of Novo Nordisk's NovoLog has been hit with an FDA complete response letter.  ...
Bayer taps Google’s quantum power for drug discovery
Bayer taps Google’s quantum power for drug discovery
The FDA has approved Sanofi Pasteur’s supplemental biologics license application (sBLA) for  its Adacel vaccine to provide immunization during the third trimester of pregnancy to prevent per...
FDA Approves FoundationOne Liquid CDx to Identify Genomic Profile in NSCLC
FDA Approves FoundationOne Liquid CDx to Identify Genomic Profile in NSCLC

The biopsy test is the first companion diagnostic approved for entrectinib for individuals who do not have an available tissue sample.

BioMarin gets first access deal in EU for gene therapy Roctavian
BioMarin gets first access deal in EU for gene therapy Roctavian
BioMarin’s has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA) reimbur...
AbbVie, Anima Biotech announce collaboration worth $580M plus
AbbVie, Anima Biotech announce collaboration worth $580M plus
AbbVie and Anima Biotech have announced that they are collaborating in a deal worth up to over $580 million to discover and develop drugs that modulate mRNA biology for three targets in cancer and...
FDA Grants Priority Review to Roche’s Glofitamab BLA in Large B-Cell Lymphoma
FDA Grants Priority Review to Roche’s Glofitamab BLA in Large B-Cell Lymphoma
The FDA has granted priority review to Roche’s biologics license application (BLA) for glofitamab for the treatment of adults with relapsed or resistant large B-cell lymphoma after two or more li...
Amgen Licenses Synaffix ADC Platform in $2 Billion Deal
Amgen Licenses Synaffix ADC Platform in $2 Billion Deal

Dutch biotech Synaffix has signed a $2 billion licensing agreement with Amgen to bring a new generation of antibody-drug conjugates (ADC) to market.

France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
Ipsen (OTC: IPSEY) has agreed to acquire Albireo Pharma Inc (NASDAQ: ALBO) at $42.00 per share in cash for an initial estimated aggregate consideration of $952 million plus one contingent value right ...
AstraZeneca buys CinCor in a deal worth up to $1.8B
AstraZeneca buys CinCor in a deal worth up to $1.8B
AstraZeneca has inked a definitive agreement to acquire cardiorenal disease player CinCor Pharma in a deal that could potentially reach $1.8 billion in total value, the companies announced Monday....
Chiesi Farmaceutici to acquire Amryt Pharma for $1.48bn
Chiesi Farmaceutici to acquire Amryt Pharma for $1.48bn

Chiesi Farmaceutici expects that the deal will expand its rare disease medicine portfolio.

Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand